What this research demonstrates is that:

Self-assembling nanotechnology is real.
Biocircuitry interface nanotech is real.
The nanowires and nanocircuits can be controlled by external electromagnetic fields.

This tech has been studied and developed for at least two decades and is backed by a large body of published research. It is therefore feasible for today’s “vaccines” to contain self-assembling nanotechnology that interfaces with human biology and is controlled by external broadcasts. This doesn’t prove that such a scenario is happening for certain, but it shows that the tech exists and is feasible.

If you’re still not convinced, consider this text from a study published nearly a decade ago, in December of 2012:

Superparamagnetic Iron Oxide Nanoparticle-Based Delivery Systems for Biotherapeutics (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167583/)

This review covers recently-developed magnetically-driven delivery systems, their unique characteristics, and their applicability for delivery of biotherapeutics. Since methods for synthesis of SPIONs and use of SPIONs as MRI contrast agents for diagnosis have been extensively reviewed [18, 19], this review focuses on the SPION-based formulations that are specific to delivery of biotherapeutics. Magnetic nanoparticles dispersed in organic solvent and aqueous solutions can be loaded within liposomes, micelles, hydrogels, and micro/nanospheres during formulation.

"First, we examine recent formulation strategies for modification of SPIONs including particle clustering and encapsulation within hydrogels, liposomes, micelles, and micro-/nano-spheres. Second, we discuss the considerations to be taken into account in design of SPION-based carriers for the delivery of specific biotherapeutics including cells, proteins/peptides, genes, and viruses. Further, we examine several commercial magnetic nanoparticles for delivery of biotherapeutics. Finally, we provide perspectives in the future directions of magnetically triggered, SPION-based carriers for biotherapeutics, and their potential clinical applications."

That was nearly a decade ago. Imagine what has been developed and deployed in the years since.

https://www.nejm.org/doi/full/10.1056/NEJMoa2109908

"Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2."

Delivery and formulation of engineered nucleic acids
Patent CA2831613A1
filed by: Moderna Therapeutics Inc
Status: Pending

https://patents.google.com/patent/CA2831613A1/en

"The invention relates to delivery methods. These methods are specifically useful in therapeutic delivery of modified nucleic acids such as modified mRNA (mmRNA)."

"There are multiple problems with prior methodologies of deliverying pharmaceutical compositions in order to achieve effective protein expression both for therapeutics and bioprocessing applications. For example, introduced DNA can integrate into host cell genomic DNA at some frequency, resulting in alterations and/or damage to the host cell genomic DNA.

Alternatively, the heterologous deoxyribonucleic acid (DNA) introduced into a cell can be inherited by daughter cells (whether or not the heterologous DNA has integrated into the chromosome) or by offspring.

In addition, there are multiple steps which must occur after delivery but before the encoded protein is made which can effect protein expression. Once inside the cell, DNA must be transported into the nucleus where it is transcribed into RNA. The RNA transcribed from DNA must then enter the cytoplasm where it is translated into protein. Not only do the multiple processing steps from administered DNA to protein create lag times before the generation of the functional protein, each step represents an opportunity for error and and damage to the cell.

Further, it is known to be difficult to obtain DNA expression in cells as frequently DNA enters a cell but is not expressed or not expressed at reasonable rates or concentrations. This can be a particular problem when DNA is introduced into primary cells or modified cell lines."

Commonalities Between COVID-19 and Radiation Injury

https://meridian.allenpress.com/radiation-research/article/195/1/1/446280/Commonalities-Between-COVID-19-and-Radiation

Ivermectin: The Wonder Drug

Fauci - History Repeating

Scott Jensen on CDC Death Certificate Guidelines for COVID-19

Kary Mullis, inventor of the PCR technique, talks about Fauci.

Kary Mullis was an American biochemist. In recognition of his invention of the polymerase chain reaction (PCR) technique, he shared the 1993 Nobel Prize in Chemistry with Michael Smith and was awarded the Japan Prize in the same year